Wednesday 8 June 2016

Patient-derived antibody appears to selectively target tumor cells

June 6, 2016 - Researchers have developed an antibody, derived from patients with early-stage lung cancer, that enlists the immune system to destroy cancer cells.

The antibody killed tumor cells in cell lines of several different cancer types and slowed tumor growth in mouse models of brain and lung cancer without obvious evidence of side effects, the researchers reported May 5 in Cell Reports. Read more here.

No comments:

Post a Comment